Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

Journal of Clinical Oncology

Volumn 13, Issue 1, 1995, Pages 210-221

  Abigerges, Dany ^b   Chabot, Guy G ^b   Armand, Jean Pierré ^a   Hérait, Patrice ^b   Gouyette, Alain ^b   Gandia, Daniel ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALIZAPRIDE; CAMPTOTHECIN; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; IRINOTECAN; LOPERAMIDE; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0028854897     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1995.13.1.210     Document Type: Article

References (54)

1. Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966
2. Li LH, Fraser TJ, Olin EJ, et al: Action of camptothecin on mammalian cells in cultures. Cancer Res 32:2643-2650, 1972
3. Drewinko B, Freireich EJ, Gottlieb JA: Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747-750, 1974
4. Gallo RC, Whang-Peng J, Adamson RH: Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789-795, 1971
5. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54:461-470, 1970
6. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC 100880). Cancer Chemother Rep 56:103-105, 1972
7. Moertel CG, Schutt AJ, Reitmeier RJ, et al: Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
8. Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972
9. Creaven PJ, Allen LM, Muggia FM: Plasma camptothecin (NSC 100880) levels during a 5-day course of treatmentrelation to dose and toxicity. Cancer Chemother Rep 56:573-578, 1972
10. Schaeppi V, Fleischman RW, Cooney DA: Toxicity of camptothecin (NSC 100 880). Cancer Chemother Rep 58:25-36, 1974
11. Creasey WA, Richards M, Gil D: Action of (S)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice. Cancer Treat Rep 67:179-182, 1983
12. Nagata H, Kaneda N, Furuta T: Action of 7-ethylcamptothecin on tumor cells and its disposition in mice. Cancer Treat Rep 71:341-348, 1987
13. Kunimoto T, Nitta K, Takeuchi M, et al: Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors. J Pharmacobiodyn 10:148-151, 1987
14. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(l-piperidino)-l-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
15. Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988
16. Bissery MC, Mathieu-Boúe A, Lavelle F: Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 32:402, 1991 (abstr)
17. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
18. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
19. Hsiang YH, Liu LF, Wall ME, et al: DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4835-4839, 1989
20. Kessel D, Bosmann HB, Lohr K: Camptothecin effects on DNA synthesis in murine leukemia cells. Biochem Biophys Acta 269:210-216, 1972
21. Wang JC: DNA topoisomerases. Ann Rev Biochem 54:665-697, 1985
22. Liu LF: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351-375, 1989
23. Gupta RS, Gupta R, Eng B, et al: Camptothecin-resistant mutants of chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48:6404-6410, 1988
24. Kanzawa F, Sugimoto Y, Minato K, et al: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human small cell lung cancercharacterization and mechanism of resistance. Cancer Res 50:5919-5924, 1990
25. Sugimoto Y, Tsukahara S, Oh-Hara T, et al: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50:6925-6930, 1990
26. Tamura H, Kohchi C, Yamada R: Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 51:1129-1136, 1991
27. Chen AY, Yu C, Potmesil M, et al: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991
28. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
29. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11, a new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
30. Taguchi T, Wakui A, Hasegawa K: Phase I clinical study of CPT-11. Research Group of CPT-11. Jpn J Cancer Chemother 17:115-120, 1990
31. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advance non-small cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
32. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1992
33. Rothenberg ML, Kuhn JG, Burris III HA, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
34. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
35. Fukuoka M, Nitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
36. Clavel M, Mathieu-Boué A, Dumortier A, et al: Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days. Proc Am Assoc Cancer Res 33:262, 1992 (abstr)
37. Culine S, de Forni M, Extra JM, et al: Phase I study of the camptothecin analog CPT-11 using a weekly schedule. Proc Am Soc Clin Oncol 11:110, 1992 (abstr)
38. Gandia D, Armand JP, Chabot GG, et al: Phase I of the new camptothecin analogue CPT-11 administered every 3 weeks. Proc Am Assoc Cancer Res 33:260, 1992, (abstr)
39. Burris HA, Rothenberg ML, Kuhn JG, et al: Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19:663-669, 1992
40. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents (review). J Natl Cancer Inst 85:271-291, 1993
41. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
42. Ogawa M, Taguchi T: Clinical studies with CPT-11The Japanese experience. Seventh NCI-EORTC Symposium on New Drugs in cancer therapy. Amsterdam, March 17-20, 1992, p 118 (abstr)
43. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47:207-214, 1981
44. Barilero I, Gandia D, Armand JP, et al: Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography - Application to plasma pharmacokinetic studies in cancer patients. J Chromatogr (Biomed Appl) 575:275-280, 1992
45. Gibaldi M: Biopharmaceutics and clinical pharmacokinetics (ed 4). Philadelphia, Lea & Febiger, 1991, p 177
46. Tsuji T, Kaneda N, Kado K, et al: CPT-11 converting enzyme from rat serum. Purification and some properties. J Pharmacobiodyn 14:341-349, 1991
47. Gandia D, Abigerges D, Armand JP, et al: CPT-11-Induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197, 1993 (letter)
48. Chen G, Portman R, Wickel A: Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion-stimulating agent. J Pharmacol Exp Ther 103:330-336, 1951
49. Kawato K: Inhibitory effect of acetylcholine-esterase by CPT-11. Annual Report, Central Research Laboratory, Dai-ichi Pharmaceutical Co, Ltd, 1989
50. Valdes Olmos R, den Hartog Jager F, Hoefnagel C, et al: Effect of loperamide and delay of bowel motility on bile acid malabsorption caused by late radiation damage and ileal resection. Eur J Nucl Med 18:346-350, 1991
51. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
52. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
53. Kaneda N, Nagata H, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720, 1990
54. Kaneda N, Yokokura T: Non linear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725, 1990